Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

3.420 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pyxis Oncology, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
From Pyxis Oncology
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in September Investor and Industry Conferences
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with... 
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges. 
Via Benzinga
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
From Pyxis Oncology
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
 
Via Benzinga
Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
 
Via Benzinga
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
Via Benzinga
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and a $13 price target, with upcoming clinical trial results. 
Via Benzinga
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024
PYXS stock results show that Pyxis Oncology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.